Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

References

• GBD. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global burden of disease study 2016. Lancet. 2016;390(10100):1211–1259. 2017 Sep 16.
   Web of Science ®Google Scholar
• Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global burden of disease study 2016. Lancet. 2017 Sep;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383–403.
   PubMed Web of Science ®Google Scholar
• Durand F. The future of liver transplantation for viral hepatitis. Liver Int Off J Int Assoc Study Liver. 2017;37(Suppl 1):130–135.
   PubMedGoogle Scholar
• Bock CT, Schwinn S, Locarnini S, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001 Mar 16;307(1):183–196.
   PubMed Web of Science ®Google Scholar
• Tang C-M. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol. 2014 May 28;20(20):6262–6278.
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang H-I, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006 Mar;130(3):678–686.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521–1531.
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004 Oct;40(4):883–891.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Liver EA for the S of the. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul 1;57(1):167–185.
   PubMed Web of Science ®Google Scholar
• Hepatitis B | guidance and guidelines | NICE [Internet]. [ cited 2019 Feb 27]. Available from: https://www.nice.org.uk/guidance/qs65
   Google Scholar
• Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006 Apr;13(4):256–263.
   PubMed Web of Science ®Google Scholar
• Tillmann HL. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int Off J Int Assoc Study Liver. 2012 Apr;32(4):544–553.
   PubMed Web of Science ®Google Scholar
• Hou J, Cui F, Ding Y, et al. Management algorithm for interrupting mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018 Oct;9.
   Google Scholar
• Sanaka S. A downside to hepatitis C virus cure? Vigilance is needed regarding hepatitis B virus reactivation, organ rejection, or hepatocellular carcinoma progression. J Infect Dis. 2018 Mar 5;217(6):857–860.
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):284–306.
   PubMed Web of Science ®Google Scholar
• Naylor PH. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2018 Jan;25(1):4–9.
   PubMed Web of Science ®Google Scholar
• Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet Lond Engl. 2005 Jan 8;365(9454):123–129.
   PubMed Web of Science ®Google Scholar
• Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2682–2695.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438–450.
   PubMed Web of Science ®Google Scholar
• Cooksley WGE, Piratvisuth T, Lee S-D, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305.
   PubMed Web of Science ®Google Scholar
• Chon YE, Kim DJ, Kim SG, et al. An observational, multicenter, cohort study evaluating the antiviral efficacy and safety in Korean patients with chronic hepatitis B receiving pegylated interferon-alpha 2a (Pegasys): TRACES study. Medicine (Baltimore). 2016 Apr;95(14):e3026.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Jia J-D, Chan HLY, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011 Nov;54(5):1591–1599.
   PubMed Web of Science ®Google Scholar
• Wiegand J. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13(2):211–220.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012 May;56(5):1006–1011.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther. 2012;17(1):9–17.
   PubMed Web of Science ®Google Scholar
• Chan HL-Y, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011 Nov;55(5):1121–1131.
   PubMed Web of Science ®Google Scholar
• Chan HLY, Ahn SH, Chang T-T, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol. 2016 May;64(5):1011–1019.
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology. 1999 Jul;30(1):244–256.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ. Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. J Hepatol. 1999 Aug 1;31(2):210–214.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials. Review of the Fialuridine (FIAU) Clinical Trials [Internet]. Washington (DC): National Academies Press (US); 1995 [cited 2018 Oct 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK232098/ Manning FJ, Swartz M, editors.
   Google Scholar
• Seto W-K, Cheung K-S, Wong DK-H, et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol. 2016 May;51(5):487–495.
   PubMed Web of Science ®Google Scholar
• Trépo C, Jezek P, Atkinson G, et al. Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol. 2000 Jun;32(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Manns MP, Neuhaus P, Atkinson GF, et al. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl Infect Dis Off J Transplant Soc. 2001 3;Mar(1):16–23.
   Google Scholar
• Krüger M, Tillmann HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplant Surg Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 1996 Jul;2(4):253–262.
   PubMedGoogle Scholar
• Puchhammer-Stöckl E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis. 2000 Jun;181(6):2063–2066.
   PubMed Web of Science ®Google Scholar
• Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 Dec 20;357(25):2576–2588.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995 Dec 21;333(25):1657–1661.
   PubMed Web of Science ®Google Scholar
• Damerow H, Yuen L, Wiegand J, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 2010 Nov;82(11):1850–1858.
   PubMed Web of Science ®Google Scholar
• Bock C-T, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology. 2002 Feb;122(2):264–273.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cho YK, Jeon WK, et al. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: real-life experience. Clin Mol Hepatol. 2017 Dec;23(4):323–330.
   PubMed Web of Science ®Google Scholar
• Hermans LE, Svicher V, Pas SD, et al. Combined analysis of the prevalence of drug-resistant hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE). J Infect Dis. 2016 Jan 1;213(1):39–48.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009 Feb;136(2):486–495.
   PubMed Web of Science ®Google Scholar
• Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013 Apr;20(4):e37–46.
   PubMed Web of Science ®Google Scholar
• But DY-K, Yuen M-F, Fung J, et al. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010 9;Sep(5):821–829.
   Google Scholar
• Goncalves J. increased risk with combination of telbivudine and pegylated interferon alfa-2a in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database. J Hepatol. 2009 Apr 1;50:S329–30.
   Web of Science ®Google Scholar
• Tsai M-C, Chen C-H, Tseng P-L, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016 Jan;22(1):95.e1–95.e7.
   Google Scholar
• Hsu C-W, Chen Y-C, Chang M-L, et al. Durability of telbivudine-associated improvement of renal function following withdrawal or switching of antivirals in chronic hepatitis B patients. Open Forum Infect Dis. 2018 Jan;5(1):271.
   Web of Science ®Google Scholar
• Lee GH, Aung MO, Dan YY, et al. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? J Med Virol. 2013 Jan;85(1):26–33.
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006 Jun 1;130(7):2039–2049.
   PubMed Web of Science ®Google Scholar
• Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010 Oct;139(4):1207–1217.
   PubMed Web of Science ®Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999 Dec 22;282(24):2305–2312.
   PubMed Web of Science ®Google Scholar
• Fontaine H, Vallet-Pichard A, Chaix M-L, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation. 2005 Oct 27;80(8):1086–1092.
   PubMed Web of Science ®Google Scholar
• Hézode C, Chevaliez S, Bouvier-Alias M, et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J Hepatol. 2007 May;46(5):791–796.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004 Sep;66(3):1153–1158.
   PubMed Web of Science ®Google Scholar
• Tillmann HL. Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Invest Drugs Lond Engl 2000. 2007 Aug;8(8):682–690.
   PubMedGoogle Scholar
• Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195.
   PubMed Web of Science ®Google Scholar
• Wong DK-H, Seto W-K, Fung J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Am Gastroenterol Assoc. 2013 Aug;11(8):1004–1010.e1.
   Web of Science ®Google Scholar
• Biver E, Calmy A, Aubry-Rozier B, et al. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss association against Osteoporosis. Osteoporos Int. 2019 Jan 2. online early
   PubMed Web of Science ®Google Scholar
• Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017. Infection. 2019 Feb;47(1):95–102.
   Web of Science ®Google Scholar
• Yuen M-F, Ahn SH, Lee KS, et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs entecavir: results from a multicentre study. J Hepatol. 2015 Mar;62(3):526–532.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Kim W, Jung YK, et al. Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic HBV infection. Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31244-8. doi:10.1016/j.cgh.2018.11.001. [Epub ahead of print]
   Google Scholar
• Jansen L, de Niet A, Stelma F, et al. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. J Hepatol. 2014 Oct;61(4):730–737.
   PubMed Web of Science ®Google Scholar
• Seifer M, Patty A, Serra I, et al. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009 Feb;81(2):147–155.
   PubMed Web of Science ®Google Scholar
• Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006 Apr 27;354(17):1807–1812.
   PubMed Web of Science ®Google Scholar
• Geipel A, Glebe D, Will H, et al. Hepatitis B virus rtI233V mutation and resistance to adefovir. N Engl J Med. 2014 Apr 24;370(17):1667–1668.
   PubMed Web of Science ®Google Scholar
• Block TM, Zhou T, Anbarasan N, et al. Evolving new strategies for the medical management of chronic hepatitis B virus infection. Gastroenterol Hepatol. 2016 Nov;12(11):679–689.
   Google Scholar
• Loggi E, Vitale G, Conti F, et al. Chronic hepatitis B: are we close to a cure? Dig Liver Dis. 2015 Oct 1;47(10):836–841.
   PubMedGoogle Scholar
• Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e antigen-negative patients. J Infect Dis. 2018 Sep 22;218(9):1480–1484.
   PubMed Web of Science ®Google Scholar
• Sarkar J, Saha D, Bandyopadhyay B, et al. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy. Indian J Med Microbiol. 2018 Jun;36(2):217–223.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322–331.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Yurdaydın C, Kabaçam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatol. 2014 Jul;60(1):87–97.
   PubMed Web of Science ®Google Scholar
• Su T-H. Unmet needs in clinical and basic hepatitis B virus research. J Infect Dis. 2017 Nov 16; 216(suppl_8):S750–6.
   PubMedGoogle Scholar
• Jun DW, Ahn SB, Kim TY, et al. Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in Hepatitis B e antigen-positive hepatitis B patients: a randomized, multicenter, phase IIIb open-label study (POTENT study). Chin Med J (Engl). 2018 Jul 20;131(14):1645–1651.
   PubMed Web of Science ®Google Scholar
• Hsu C-W, Su W-W, Lee C-M, et al. Phase IV randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018 Jul;117(7):588–597.
   PubMed Web of Science ®Google Scholar
• Ouzan D, Pénaranda G, Joly H, et al. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013 Dec;58(4):713–717.
   PubMed Web of Science ®Google Scholar
• Tatsukawa Y, Tsuge M, Kawakami Y, et al. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study. Antivir Ther. 2018 Jun 1. online early
   PubMed Web of Science ®Google Scholar
• de Niet A, Jansen L, Stelma F, et al. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2(8):576–584.
   PubMed Web of Science ®Google Scholar
• Tseng T-C. Elimination of hepatitis B: is it a mission possible? BMC Med. 2017;15(1):53.
   PubMedGoogle Scholar
• Al Mahtab M. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PloS One. 2018;13(8):e0201236.
   PubMed Web of Science ®Google Scholar
• Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012 Jan;56(1):115–122.
   PubMed Web of Science ®Google Scholar
• Giersch K, Helbig M, Volz T, et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J Hepatol. 2014 Mar;60(3):538–544.
   PubMed Web of Science ®Google Scholar
• Hepatitis B Foundation. [cited 2019 Feb 27]. Available from: http://www.hepb.org/treatment-and-management/drug-watch/
   Google Scholar